Literature DB >> 31016637

The Role of Interleukin-9 in Cancer.

Jacob E Lee1, Ziwen Zhu2, Qian Bai2, Tucker J Brady1, Huaping Xiao1,3, Mark R Wakefield2, Yujiang Fang4,5.   

Abstract

Interluekin-9 (IL-9) is produced predominantly by helper T cells such as Th2 and Th9 cells. It normally functions through the activation of a JAK/STAT pathway and plays a critical role in immunity and the pathogenesis of cancer. In cancer, it yields different responses depending on the cancer cell line involved. This review is a summary of what is known about the involvement of IL-9 in various cancer cell lines as well as its role in immunity with a focus on allergic responses.

Entities:  

Keywords:  Cancer; Inflammation; Interleukin 9

Mesh：

Substances：

Year:  2019        PMID： 31016637     DOI： 10.1007/s12253-019-00665-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  41 in total

1.  IL-1 serves as a secondary signal for IL-9 expression.

Authors:  E Schmitt; H U Beuscher; C Huels; P Monteyne; R van Brandwijk; J van Snick; E Ruede
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

2.  IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma.

Authors:  E Schmitt; T Germann; S Goedert; P Hoehn; C Huels; S Koelsch; R Kühn; W Müller; N Palm; E Rüde
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

3.  Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Authors:  Dominique B Hoelzinger; Ana Lucia Dominguez; Peter A Cohen; Sandra J Gendler
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

4.  Induction of enhanced immunity to intestinal nematodes using IL-9-producing dendritic cells.

Authors:  Melanie D Leech; Richard K Grencis
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

5.  Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18.

Authors:  B R Lauwerys; N Garot; J C Renauld; F A Houssiau
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

6.  Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.

Authors:  Alexander Visekruna; Josephine Ritter; Tatjana Scholz; Lucia Campos; Anna Guralnik; Lucia Poncette; Hartmann Raifer; Stefanie Hagner; Holger Garn; Valerie Staudt; Tobias Bopp; Sebastian Reuter; Christian Taube; Karin Loser; Magdalena Huber
Journal:  Eur J Immunol       Date:  2013-01-31       Impact factor: 5.532

7.  IL-9 as a mediator of Th17-driven inflammatory disease.

Authors:  Elizabeth C Nowak; Casey T Weaver; Henrietta Turner; Sakhina Begum-Haque; Burkhard Becher; Bettina Schreiner; Anthony J Coyle; Lloyd H Kasper; Randolph J Noelle
Journal:  J Exp Med       Date:  2009-07-13       Impact factor: 14.307

8.  Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells.

Authors:  Tatiana G Jones; Jenny Hallgren; Alison Humbles; Timothy Burwell; Fred D Finkelman; Pilar Alcaide; K Frank Austen; Michael F Gurish
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

9.  IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells.

Authors:  Wassim Elyaman; Elizabeth M Bradshaw; Catherine Uyttenhove; Valérie Dardalhon; Amit Awasthi; Jaime Imitola; Estelle Bettelli; Mohamed Oukka; Jacques van Snick; Jean-Christophe Renauld; Vijay K Kuchroo; Samia J Khoury
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

10.  IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation.

Authors:  Jan-Eric Turner; Peter J Morrison; Christoph Wilhelm; Mark Wilson; Helena Ahlfors; Jean-Christophe Renauld; Ulf Panzer; Helena Helmby; Brigitta Stockinger
Journal:  J Exp Med       Date:  2013-11-18       Impact factor: 14.307
View more
  7 in total

Review 1.  The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma.

Authors:  Kyle P D'mello; Lei Zhao; Erin C Kaser; Ziwen Zhu; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Med Oncol       Date:  2021-04-09       Impact factor: 3.064

2.  Interleukin-9 Inhibits Lung Metastasis of Melanoma through Stimulating Anti-Tumor M1 Macrophages.

Authors:  Sang Min Park; Van Anh Do-Thi; Jie-Oh Lee; Hayyoung Lee; Young Sang Kim
Journal:  Mol Cells       Date:  2020-05-31       Impact factor: 5.034

3.  Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis.

Authors:  Baptiste Gouyou; Tiziano Ongaro; Samuele Cazzamalli; Roberto De Luca; Anne Kerschenmeyer; Philippe Valet; Alessandra Villa; Dario Neri; Mattia Matasci
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-21

4.  Bone Marrow Plasma Cytokine Signature Profiles in Severe Aplastic Anemia.

Authors:  Bingnan Liu; Yuanyuan Shao; Zixuan Liu; Chunyan Liu; Tian Zhang; Rong Fu
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411

5.  The Role of IL-9 Polymorphisms and Serum IL-9 Levels in Carcinogenesis and Survival Rate for Laryngeal Squamous Cell Carcinoma.

Authors:  Agne Pasvenskaite; Rasa Liutkeviciene; Greta Gedvilaite; Alvita Vilkeviciute; Vykintas Liutkevicius; Virgilijus Uloza
Journal:  Cells       Date:  2021-03-09       Impact factor: 6.600

6.  Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma.

Authors:  Qian Zhang; Lanlan Yang; Siqi Liu; Mengyao Zhang; Zhenjing Jin
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 7.  Interleukin (IL)-9 Supports the Tumor-Promoting Environment of Chronic Lymphocytic Leukemia.

Authors:  Laura Patrussi; Nagaja Capitani; Cosima T Baldari
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.